The official advocacy organization for pharmacist women in the United States
Pharmacist Moms Group™
45,000+ Members
Over 6 Million posts, comments and reactions in 2020
60,000+ Followers on social media platforms
The Largest Community of Women Pharmacists in the US
Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.
While we may not be able to control what happens to us, we can ALWAYS control how we respond. Working on self-awareness and self-improvement will certainly create positive habits to help you when you are stuck.
Read on to learn more about Jennifer’s path to pharmacy ownership, and to learn how COVID-19 and the Oregon wildfires have impacted her business.
Miss America 2020, Camille Schrier, has been a proud, self-described “science nerd” for as long as she can remember. We caught up with Camille to get a student’s perspective on the future of the profession.
Sasha Watson, PharmD, BCOP, discusses the emerging role of circulating tumor DNA (ctDNA) in colon cancer, highlighting its potential to enhance precision oncology by improving early detection, guiding adjuvant therapy decisions, and monitoring disease recurrence and treatment resistance.
Updates on April 30, 2025, introduce changes to treatment regimens, sequencing flexibility, febrile neutropenia risk assessments, and drug-specific safety and supportive care guidance.
Explore the role of JAK inhibitors in myelofibrosis treatment, focusing on optimizing dosages and managing adverse effects for better patient outcomes.
Specialty pharmacies can leverage advanced analytics, AI, and comprehensive data insights to create targeted clinical programs.
Specialty distributors provide strategic partnerships that enhance pharmaceutical manufacturers' ability to bring innovative medicines to market.
A phase 1b study demonstrated that continuous subcutaneous infusion of low-dose lenalidomide in patients with relapsed or refractory (R/R) multiple myeloma achieved promising efficacy with significantly reduced hematologic toxicity compared to conventional oral dosing.
Official Media Partner
.png)
Official CE Partner
Founder of Women Pharmacist Day
